- Home
- NVNO vs ATNM Comparison
NVNO vs ATNM Comparison
Compare NVNO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- ATNM
- Stock Information
- Founded
- NVNO 1987
- ATNM 2000
- Country
- NVNO United States
- ATNM United States
- Employees
- NVNO N/A
- ATNM N/A
- Industry
- NVNO Medical/Dental Instruments
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- NVNO Health Care
- ATNM Health Care
- Exchange
- NVNO Nasdaq
- ATNM Nasdaq
- Market Cap
- NVNO 59.4M
- ATNM 56.5M
- IPO Year
- NVNO N/A
- ATNM N/A
- Fundamental
- Price
- NVNO $3.30
- ATNM $1.46
- Analyst Decision
- NVNO
- ATNM Strong Buy
- Analyst Count
- NVNO 0
- ATNM 5
- Target Price
- NVNO N/A
- ATNM $10.20
- AVG Volume (30 Days)
- NVNO 117.4K
- ATNM 245.2K
- Earning Date
- NVNO 10-31-2024
- ATNM 11-14-2024
- Dividend Yield
- NVNO N/A
- ATNM N/A
- EPS Growth
- NVNO N/A
- ATNM N/A
- EPS
- NVNO N/A
- ATNM N/A
- Revenue
- NVNO N/A
- ATNM $81,000.00
- Revenue This Year
- NVNO N/A
- ATNM $186.10
- Revenue Next Year
- NVNO N/A
- ATNM $19,248.94
- P/E Ratio
- NVNO N/A
- ATNM N/A
- Revenue Growth
- NVNO N/A
- ATNM N/A
- 52 Week Low
- NVNO $3.01
- ATNM $1.33
- 52 Week High
- NVNO $6.97
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- NVNO 43.55
- ATNM 33.81
- Support Level
- NVNO $3.24
- ATNM $1.38
- Resistance Level
- NVNO $3.75
- ATNM $1.97
- Average True Range (ATR)
- NVNO 0.18
- ATNM 0.11
- MACD
- NVNO 0.02
- ATNM -0.04
- Stochastic Oscillator
- NVNO 12.62
- ATNM 5.08
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.